A federal judge in California has ruled in favor of Apple Inc., granting summary judgment in a case where workers sought to include restricted stock units in their overtime pay calculations. The court determined that the Fair Labor Standards Act's "gift" and "equity" exceptions allowed Apple to exclude these stock values from regular rate of pay calculations. This decision addresses a "novel question" regarding federal wage law.

New analysis from the CATALYST clinical trial indicates that Korlym (mifepristone) can help lower blood sugar and promote weight loss in diabetes patients with high cortisol levels who are also on GLP-1 targeting medications. Corcept Therapeutics presented these findings, which suggest that modulating cortisol can improve metabolic parameters even for those with poorly controlled type 2 diabetes despite powerful GLP-1 therapies. Korlym works by blocking cortisol receptors and has shown better results than placebo in reducing HbA1c, body weight, waist circumference, and BMI.

S&P Global (SPGI) is highlighted as a strong wide-moat financial stock to consider. The article emphasizes its multiple competitive advantages, including its dominant credit ratings and indexing businesses, along with its Market Intelligence segment. Despite a recent stock price dip, its current valuation makes it an attractive buying opportunity for investors.

Realty Income (O) presents an attractive investment for retirees with a 5.3% yield and a strong track record of 670 consecutive monthly dividends. The company has demonstrated dividend safety through various economic challenges, supported by a healthy 73% AFFO payout ratio and projected 9% total operational return for 2026. Despite elevated leverage, the shifting interest rate environment and impressive occupancy rates suggest a dependable monthly payout for income-focused investors.

This article argues that investors should consider Pfizer (NYSE:PFE) over Eli Lilly (NYSE:LLY), especially given current market volatility. While Eli Lilly's stock is soaring due to GLP-1 drugs, it presents a concentrated risk with two primary revenue drivers and a high valuation. In contrast, Pfizer offers a diversified portfolio, recent patent cliff resolution, ongoing restructuring, active insider buying, and a strong 6.6% dividend yield.

Charles Schwab (SCHW) stock rose 3.4% due to a general market rebound driven by cooler inflation data, renewed focus on Schwab's strong business performance, and expectations of supportive market conditions for trading and net interest revenue. The article also provides detailed insider trading activity, institutional holdings changes, congressional stock trading, and analyst ratings/price targets for SCHW.

Wells Fargo announced a $1 million donation to support skilled trades, training, and workforce development in Pennsylvania, continuing its partnership with the mikeroweWORKS Foundation. This initiative aims to address the growing demand for skilled workers in the state and builds on over $10 million Wells Fargo has contributed nationwide to advance skilled trades. U.S. Senator Dave McCormick lauded the investment, highlighting its potential to strengthen communities and provide good-paying jobs.

Representative Mike Kelly of Pennsylvania sold Bristol-Myers Squibb (NYSE: BMY) stock worth between $16,002 and $65,000, with the transaction occurring on May 7, 2026. This sale was filed in June 2026. Congressional transactions, while not primary investment advice, can offer insights into a stock's potential performance for investors.

Senator Gary C. Peters from Michigan recently purchased between $1,001 and $15,000 worth of Kraft Heinz (NASDAQ: KHC) stock, with the transaction occurring on May 21, 2026. This purchase is part of his 23 stock transactions totaling over $135,000 in the last three years. Congressional transactions, while not primary investment advice, offer insight into potential stock movements as representatives are required to disclose their trades.

Robert K. Shearer, a Director at Church & Dwight Co (NYSE: CHD), recently exercised stock options for 8,600 shares, valuing the transaction at $169,850 based on current share prices. This information was disclosed in an SEC filing. The article also provides a financial overview of Church & Dwight Co, highlighting its revenue growth, profitability indicators, valuation metrics, and the significance of insider transactions.